OncoMatch/Clinical Trials/NCT06663306
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Is NCT06663306 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Pemetrexed and Bevacizumab for lung cancer (nsclc).
Treatment: Pemetrexed · Bevacizumab — This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: systemic anti-tumor treatment — for leptomeningeal metastasis
Unsatisfactory efficacy of LM,which defined as disease progression in LM,or LM-related neurological progression, while patients received standard systemic anti-tumor treatment
Cannot have received: pemetrexed intrathecal injection (pemetrexed)
History of pemetrexed and/or bevacizumab intrathecal Injection
Cannot have received: bevacizumab intrathecal injection (bevacizumab)
History of pemetrexed and/or bevacizumab intrathecal Injection
Cannot have received: brain/spinal cord radiation therapy
Brain/spinal cord radiation therapy within 1 week before enrollment
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L, neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L
Kidney function
Creatinine≤ 2.0 × ULN, or Creatinine clearance rate (CrCl) ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN
The laboratory test results meet the following criteria: Hemoglobin ≥ 90 g/L, neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L; Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN ; Creatinine≤ 2.0 × ULN,or Creatinine clearance rate (CrCl) ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06663306 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pemetrexed intrathecal injection, bevacizumab intrathecal injection, brain/spinal cord radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages